Lab Studies

Novaerus technology has been shown to safely and effectively reduce bacteria, viruses, VOCs, and particulate matter in dozens of independent laboratory tests. In case studies and clinical trials, our products have been demonstrated to reduce infections and improve wellbeing in real-world settings. 

SARS-CoV-2 Reduction

To evaluate the efficacy of the Defend 1050 at reducing SARS-CoV-2, the virus causing COVID-19.

SARS-CoV-2 Surrogate Reduction

To evaluate the efficacy of the NV1050 at reducing aerosolized MS2 bacteriophage, a surrogate for SARS-CoV-2, the virus causing COVID-19.

Air Exchange

To assess the time taken for the NV950 (NV800/900) to treat the air of a 22.65m3 (800 ft3) room.

Airborne Allergen Reduction

To evaluate the efficacy of the NV800/NV900 on reducing airborne allergens.

Aspergillus niger Spore Reduction

To evaluate the efficacy of the Novaerus NV1050 system against aerosolized Aspergillus niger spores.

Bioaerosols Reduction

To evaluate the efficacy of the NV900 on neutralizing bioaerosols. The device was assessed on four aerosolized biologicals: Staphylococcus epidermidis, MS2 bacteriophage, Aspergillus niger fungus, and Bacillus subtilis endospores.

Clostridium difficile Spore Reduction

To assess the performance of the NV1050 in removing aerosolized Clostridium difficile spores.

Influenza A Reduction

To evaluate the efficacy of the NV1050 on removing Influenza A.

Formaldehyde Reduction

This in vitro study characterized the removal efficacy of formaldehyde by the Novaerus NV1050 system. Novaerus’s NV1050 system is designed to eliminate harmful gases in order to purify rooms and create safe environments for occupants.

Formaldehyde Reduction

To evaluate the efficacy of the NV800/NV900 on reducing formaldehyde.

Measles Virus Reduction

To assess the performance of the NV1050 in removing aerosolised Human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus.

Methicillin-resistant Staphyloco-ccus aureus (MRSA) Reduction

To evaluate the efficacy of the NV900 on reducing methicillin-resistant Staphylococcus aureus (MRSA).

Mycobacterium tuberculosis Bacteria Reduction

To assess the performance of the NV1050 in removing aerosolised Mycobacterium smegmatis, a surrogate for Mycobacterium tuberculosis.

Mycobacteri-um tuberculosis Inactivation

To evaluate the efficacy of the NV200 on reducing Mycobacterium tuberculosis.

Nitrogen Dioxide Reduction

This in vitro study characterized the removal efficacy of Nitrogen Dioxide (NO2) by the Novaerus NV1050 system. Novaerus’s NV1050 system is designed to eliminate harmful gases in order to purify rooms and create safe environments for occupants. The study included three (3) trials and a control run against NO2.

Particle Reduction

To evaluate the particulate and molecular efficiency of the NV1050 in a test chamber using DEHS.

Phi X 174 Virus Reduction

To assess the performance of the NV1050 in reducing phi X 174 virus.

Staphylococcus epidermidis Bacteria Reduction

To evaluate the efficacy of the NV1050 in reducing airborne Staphylococcus epidermidis bacteria, a surrogate for methicillin-resistant Staphylococcus aureus (MRSA).

Staphylococcus epidermidis Bacteria Reduction

To evaluate the efficacy of the NV800 in reducing Staphylococcus epidermidis aerosols, a surrogate for methicillin-resistant Staphylococcus aureus (MRSA).

Staphylococcus Epidermidis Bacteria Reduction

To assess the performance of the NV1050 in reducing Staphylococcus epidermidis bacteria.

VOC Reduction

To evaluate the particulate and molecular efficiency of the NV1050 in a test chamber using a VOC.